26
|
Kadota A, Miura K, Fujiyoshi A, Hisamatsu T, Kadowaki S, Zaid M, Miyagawa N, Kondo K, Kunimura A, Okamura T, Ueshima H. P4448The association of coronary artery calcification progression, albuminuria and estimated glomerular filtration rate among general population. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Hasegawa H, Ando M, Yatabe Y, Mitani S, Honda K, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site. Clin Oncol (R Coll Radiol) 2018; 30:667-673. [PMID: 30196846 DOI: 10.1016/j.clon.2018.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Revised: 05/14/2018] [Accepted: 06/06/2018] [Indexed: 01/20/2023]
Abstract
AIMS Although platinum-based combination chemotherapies are commonly used for unfavourable subsets of cancer of unknown primary (CUP), the prognosis remains poor. Several studies have suggested that gene expression profiling or immunohistochemistry was useful for the prediction of primary sites in CUP, and site-specific therapy based on predicted primary sites might improve overall outcomes. In Japan, to identify primary sites, immunohistochemical tests were commonly used for CUP in clinical practice. However, it is unclear whether site-specific therapy based on predicted primary sites by pathological examination contributes survival benefit for unfavourable CUP subsets. PATIENTS AND METHODS In this study, 122 patients with unfavourable subsets of CUP were retrospectively reviewed. Ninety patients assigned to cohort A after July 2012 had received chemotherapy according to predicted primary sites; 32 patients assigned to cohort B before June 2012 had received platinum-based empiric chemotherapy. RESULTS In cohort A, 56 patients (62.2%) with predicted primary sites by pathological examination received site-specific therapy; 34 patients (37.8%) with unpredictable primary sites received platinum-based empiric chemotherapy, the same as cohort B. The median overall survival was 20.3 months in patients with predictable primary sites in cohort A and 10.7 months in those of cohort B, with a significant difference between these cohorts (P = 0.03, adjusted hazard ratio = 0.57, 95% confidence interval 0.34-0.94). CONCLUSION Site-specific therapy based on predicted primary sites by pathological examination could improve prognosis in patients with an unfavourable subset of CUP.
Collapse
|
28
|
Mitani S, Oze I, Kadowaki S, Masuishi T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Makita C, Kodaira T, Uemura N, Abe T, Muro K. Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Narita Y, Sasaki E, Yatabe Y, Kato K, Okano H, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Ito S, Muro K. PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Mitani S, Taniguchi H, Honda K, Masuishi T, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Muro K. Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Yamashita A, Murakami T, Kadowaki S, Yoshida K, Ito E, Matsuda N, Chang F, Hattori N, Miyai I, Ugawa Y. Spike-timing dependent plasticity at spinal motoneurons. Brain Stimul 2017. [DOI: 10.1016/j.brs.2017.01.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
34
|
Fujiwara Y, Ishigami H, Fukushima R, Nashimoto A, Yabusaki H, Imamoto H, Imano M, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Kitayama J. Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Mitani S, Kadowaki S, Oze I, Masuishi T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Makita C, Kodaira T, Uemura N, Abe T, Muro K. Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: A long-term comparison. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Ebisutani C, Ito I, Kitaichi M, Tanabe N, Mishima M, Kadowaki S. A case of non-specific interstitial pneumonia with recurrent gastric carcinoma and anti-Jo-1 antibody positive myositis. Respir Investig 2016; 54:289-93. [PMID: 27424830 DOI: 10.1016/j.resinv.2016.02.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 02/02/2016] [Accepted: 02/16/2016] [Indexed: 12/01/2022]
Abstract
We report the first case of non-specific interstitial pneumonia (NSIP) in a patient with cancer-associated myositis (CAM) that emerged along with the recurrence of the cancer. A 60-year-old woman, with a history of partial gastrectomy for gastric cancer 11 years ago, presented with exertional dyspnea with anti-Jo-1 antibody-positive myositis. Surgical lung biopsy showed NSIP with metastatic gastric cancer. Accordingly, her condition was diagnosed as CAM with cancer recurrence. In patients with a history of cancer, development of myositis may indicate cancer recurrence; therefore, careful observation would be necessary.
Collapse
|
37
|
Komori A, Taniguchi H, Kito Y, Hamauchi S, Masuishi T, Hasegawa H, Mitani S, Narita Y, Kadowaki S, Ura T, Ando M, Mori K, Yasui H, Muro K, Yamazaki K. 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Narita Y, Kadowaki S, Oze I, Taniguchi H, Ura T, Ando M, Ito S, Yatabe Y, Tajika M, Muro K. 205P Development of nomograms including HER2 status for predicting survival in metastatic gastric cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Taniguchi H, Hasegawa H, Masuishi T, Narita Y, Komori A, Kadowaki S, Ura T, Muro K. P-232 Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Nomura M, Abe T, Kodaira T, Oze I, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Takahari D, Ura T, Andoh M, Kawai R, Uemura N, Tomita N, Tachibana H, Tanaka T, Tajika M, Niwa Y, Muro K. Comparison of Surgery with Definitive Chemoradiotherapy for Potentially Resectable Esophageal Cancer: a Propensity-Score Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Shinozaki E, Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Sasaki T, Shitara K, Nagatsuma A, Yoshino T, Ochiai A, Ohtsu A. Prognostic Impact of Her2, Egfr, and C-Met Status on Overall Survival of Advanced Gastric Cancer Patients Treated with Standard Chemotherapy Without Trastuzumab in a First-Line Treatment: a Japanese Multicenter Collaborative Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Kadowaki S, Enomoto H, Moriya A, Murakami T, Nakamura K, Naktani-Enomoto S, Mochizuki H, Kobayashi S, Ugawa Y. P1064: Phasic muscle contraction influence upon the quadripulse stimulation (QPS) after effects. Clin Neurophysiol 2014. [DOI: 10.1016/s1388-2457(14)51093-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Nitta S, Ando M, Yamaguchi K, Kondo C, Taniguchi H, Kadowaki S, Takahari D, Ura T, Muro K. Cancer of Unknown Primary Site: Review of Consecutive Cases in Aichi Cancer Center Hospital. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Komori A, Kondo C, Yamaguchi K, Taniguchi H, Kadowaki S, Takahari D, Ura T, Ando M, Muro K. Feasibility of Oxaliplatin Containing Regimens for Advanced Gastric Cancer (AGC) with Peritoneal Metastases. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Narumi T, Watanabe T, Arimoto T, Kadowaki S, Otaki Y, Honda Y, Hasegawa H, Honda S, Kubota I. Obesity paradox is not recognized in chronic heart failure patients with metabolic syndrome. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kadowaki S, Watanabe T, Narumi T, Otaki Y, Honda Y, Honda S, Hasegawa M, Shishido T, Kubota I. Combination of heart-type fatty acid binding protein and QRS prolongation can risk-stratify patients with chronic heart failure. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Jpn J Clin Oncol 2012; 42:1146-51. [DOI: 10.1093/jjco/hys160] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Ooki A, Yamashita K, Yamaguchi K, Asayama M, Kadowaki S, Hara H, Yamada-murano T, Arima M, Tada M, Watanabe M. Functional Analysis of Reprimo as a Suppressor Gene in Gastric Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32381-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Yamazaki K, Bando H, Shinozaki E, Nishina T, Kadowaki S, Yuki S, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Yoshino T. Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring KRAS Codon61, KRAS Codon146, BRAF, NRAS or PIK3CA Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32332-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
50
|
Shinozaki E, Bando H, Nishina T, Yamazaki K, Kadowaki S, Yuki S, Kajiura S, Tsuchihara K, Fujii S, Yoshino T. Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring Kras CODON61, Kras CODON146, Braf, Nras or PIK3CA Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33185-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|